78 related articles for article (PubMed ID: 3515665)
21. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
[TBL] [Abstract][Full Text] [Related]
22. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
[TBL] [Abstract][Full Text] [Related]
23. Use of cyclosporine for prevention of graft-versus-host disease after allogeneic bone marrow transplantation.
Gluckman E; Devergie A; Lokiec F
Transplant Proc; 1988 Jun; 20(3 Suppl 3):461-9. PubMed ID: 3291282
[No Abstract] [Full Text] [Related]
24. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
Martin-Algarra S; Bishop MR; Tarantolo S; Cowles MK; Reed E; Anderson JR; Vose JM; Bierman P; Armitage JO; Kessinger A
Exp Hematol; 1995 Dec; 23(14):1503-8. PubMed ID: 8542938
[TBL] [Abstract][Full Text] [Related]
25. High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.
Zander AR; Berger C; Kröger N; Stockshläder M; Krüger W; Horstmann M; Grimm J; Zeller W; Kabisch H; Erttmann R; Schönrock P; Kuse R; Braumann D; Illiger HJ; Fiedler W; de Witt M; Hossfeld KD; Weh HJ
Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2671-5. PubMed ID: 10068272
[TBL] [Abstract][Full Text] [Related]
26. [Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in patients with leukemia].
Löwenberg B; Sizoo W; Wagemaker G; Sintnicolaas K; Hendriks WD; Hagenbeek A
Ned Tijdschr Geneeskd; 1986 May; 130(19):872-6. PubMed ID: 3520349
[No Abstract] [Full Text] [Related]
27. Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time--a report of the acute leukemia working party of the European group for blood and marrow transplantation (EBMT).
Frassoni F; Labopin M; Gluckman E; Prentice HG; Vernant JP; Zwaan F; Granena A; Gahrton G; De Witte T; Gratwohl A; Reiffers J; Gorin NC
Bone Marrow Transplant; 1996 Jan; 17(1):13-8. PubMed ID: 8673048
[TBL] [Abstract][Full Text] [Related]
28. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
[TBL] [Abstract][Full Text] [Related]
29. [Prophylaxis with FK-506 for graft-versus-host disease after transplantation of bone marrow from unrelated donors].
Hamazaki T; Yagi K; Inoue M; Sakata N; Okamura T; Yasui M; Sasabe M; Kishimoto T; Inoue A; Kawa K
Rinsho Ketsueki; 2000 May; 41(5):430-6. PubMed ID: 10879106
[TBL] [Abstract][Full Text] [Related]
30. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors.
Koehler M; Hurwitz CA; Krance RA; Coustan-Smith E; Williams LL; Santana V; Ribeiro RC; Brenner MK; Heslop HE
Bone Marrow Transplant; 1994 May; 13(5):571-5. PubMed ID: 7519937
[TBL] [Abstract][Full Text] [Related]
31. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease.
Aschan J; Ringdén O
Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365
[TBL] [Abstract][Full Text] [Related]
32. Clinical and pharmacological risk factors for acute graft-versus-host disease after paediatric bone marrow transplantation from matched-sibling or unrelated donors.
Martin P; Bleyzac N; Souillet G; Galambrun C; Bertrand Y; Maire PH; Jelliffe RW; Aulagner G
Bone Marrow Transplant; 2003 Nov; 32(9):881-7. PubMed ID: 14561988
[TBL] [Abstract][Full Text] [Related]
33. Re: Twenty-year follow-up in patients with aplastic anemia given marrow grafts from HLA-identical siblings and randomized to receive methotrexate/cyclosporine or methotrexate alone for prevention of graft-versus-host disease.
Sorror ML; Leisenring W; Deeg HJ; Martin PJ; Storb R
Biol Blood Marrow Transplant; 2005 Jul; 11(7):567-8. PubMed ID: 15983557
[No Abstract] [Full Text] [Related]
34. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation.
Schwinghammer TL; Bloom EJ
Clin Pharm; 1993 Oct; 12(10):736-61. PubMed ID: 8258255
[TBL] [Abstract][Full Text] [Related]
35. Factors influencing the haematological recovery after allogeneic bone marrow transplantation in leukaemia patients treated with methotrexate-containing GVHD prophylaxis: a single-centre experience.
Hassan HT; Krog C; Stockschläder M; Schleimer B; Zeller W; Krüger W; Erttmann R; Zander AR
Anticancer Res; 1997; 17(1B):589-99. PubMed ID: 9066585
[TBL] [Abstract][Full Text] [Related]
36. Individualized prophylaxis against graft-versus-host disease in leukemic marrow transplant recipients.
Aschan J; Ringdén O; Andström E; Ljungman P; Lönnqvist B; Remberger M
Bone Marrow Transplant; 1994 Jul; 14(1):79-87. PubMed ID: 7951124
[TBL] [Abstract][Full Text] [Related]
37. [Unrelated donor stem cell transplantation in children: low toxicity using a GvHD-prophylaxis regimen with CSA, MTX, metronidazole,iv-immunoglobulin and ATG].
Graf Finckenstein F; Zabelina T; Dürken M; Dahlke J; Kröger N; Krüger W; Janka-Schaub G; Erttmann R; Zander AR; Kabisch H
Klin Padiatr; 2002; 214(4):206-11. PubMed ID: 12165903
[TBL] [Abstract][Full Text] [Related]
38. [Prevention of graft-versus-host disease following allogeneic bone marrow transplantation by removal of T-cells].
de Gast GC; Verdonck LF; van Kempen-Harteveld ML; Gerritsen H; Dekker AW
Ned Tijdschr Geneeskd; 1986 May; 130(19):868-71. PubMed ID: 3520348
[No Abstract] [Full Text] [Related]
39. Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia.
Jillella AP; Doria R; Khan K; Zelterman D; Ahmad YH; Smith BR; Holmes W; Becker P; Roberts KB; Rappeport JM
Bone Marrow Transplant; 1999 Jun; 23(11):1095-100. PubMed ID: 10382947
[TBL] [Abstract][Full Text] [Related]
40. Combination graft-versus-host disease prophylaxis using immunotoxin (anti-CD5-RTA [Xomazyme-CD5]) plus methotrexate and cyclosporine or prednisone after unrelated donor marrow transplantation.
Weisdorf D; Filipovich A; McGlave P; Ramsay N; Kersey J; Miller W; Blazar B
Bone Marrow Transplant; 1993 Nov; 12(5):531-6. PubMed ID: 8298565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]